View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
DOJ/DEA RIN: 1117-AB81 Publication ID: Spring 2023 
Title: Implementation of the Designer Anabolic Steroid Control Act of 2014 
Abstract:

On December 18, 2014, the Designer Anabolic Steroid Control Act of 2014 (DASCA) became law.  The Act amended the Controlled Substances Act to revise and add specified substances to the definition of anabolic steroid.  The Act provided a new mechanism for temporary and permanent scheduling of anabolic steroids, and added specific labeling requirements for products containing anabolic steroids.  The Drug Enforcement Administration (DEA) is publishing this rule to amend and reorganize its regulations to make them consistent with DASCA regarding the updated definition, specific substances, criteria and timeframes applicable to temporary and permanent scheduling of anabolic steroids, and labeling requirements.

 
Agency: Department of Justice(DOJ)  Priority: Substantive, Nonsignificant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Undetermined  Unfunded Mandates: No 
CFR Citation: 21 CFR 1300    21 CFR 1302    21 CFR 1308   
Legal Authority: 21 U.S.C. 802    21 U.S.C. 811    21 U.S.C. 812    21 U.S.C. 821    21 U.S.C. 825    21 U.S.C. 842    21 U.S.C. 871(b)    21 U.S.C. 951    21 U.S.C. 956(b)    21 U.S.C. 958(e)   
Legal Deadline:  None
Timetable:
Action Date FR Cite
Final Action  07/00/2023 
Additional Information: DEA Docket number 481
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
RIN Information URL: DPE@dea.gov   Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Scott A. Brinks
Section Chief, Regulatory Drafting and Support Section, Diversion Control Division
Department of Justice
Drug Enforcement Administration
8701 Morrissette Drive,
Springfield, VA 22152
Phone:571 362-8209
Email: scott.a.brinks@dea.gov